[Research progress of mesenchymal stem cell-derived exosomes in the treatment of inflammatory bowel disease].

Abstract

Inflammatory bowel disease (IBD) is a chronic nonspecific inflammatory disease of the intestine, with unknown etiology and the incidence is increasing year by year. Traditional treatment has limited effect. Mesenchymal stem cell-derived exosomes (MSC-Exos) are a group of nano-sized extracellular vesicles. Their function is equivalent to that of mesenchymal stem cells (MSCs), with no tumorigenicity and high safety. They represent a novel cell-free therapy. It has been shown that MSC-Exos can improve IBD by effects including anti-inflammation, antioxidant stress, repairing intestinal mucosal barrier and immune regulation. However, their clinical application still faces some problems, such as the lack of standardized production technology, lack of specific IBD diagnostic molecules and anti-intestinal fibrosis.